yingweiwo

New1

New1

New1 related products

Structure Cat No. Product Name CAS No. Product Description
MARK Substrate V29112 MARK Substrate 847991-34-8 MARK Substrate is a MARK substrate.
Mast Cell Degranulating Peptide HR-2 V29252 Mast Cell Degranulating Peptide HR-2 80388-04-1 Mast Cell Degranulating Peptide HR-2 is a 14-membered linear peptide extracted from the venom of the Eastern bumble bee that degranulates mast cells, thereby triggering histamine release.
Masticadienediol V25067 Masticadienediol 6138-94-9 Masticadienediol is a novel and potent tetracyclic triterpene
Masupirdine free base V29575 Masupirdine free base 701205-60-9 Masupirdine free base (SUVN-502 free base) is a potent, selective, orally bioavailable and brain barrier-penetrating 5-HT6 receptor blocker (antagonist) (Ki for human 5-HT6 receptor is 2.04 nM).
MAT2A抑制剂 V25063 MAT2A inhibitor 2201057-10-3 MAT2A inhibitor is a novel and potent methionine adenosyltransferase 2A (MATA2) inhibitor (IC50< l00 nM).
Matlystatin A V25068 Matlystatin A 140626-94-4 Matlystatin A is a novel and potent aminopeptidase inhibitor with activity against aminopeptidase N and matrix metalloproteinases (MMP).
Mavelertinib (PF06747775) V25072 Mavelertinib (PF06747775) 1776112-90-3 Mavelertinib (formerly PF-06747775; PF06747775) is amutant-selective,orally bioactive and irreversible/covalent inhibitor of the epidermal growth factor receptor (EGFR) T790M.
Mavoglurant V13786 Mavoglurant 543906-09-8 Mavoglurant (AFQ-056; AFQ056) is a potent and non-competitive mGlu5 (metabotropic glutamate receptor 5) receptor antagonist (IC50=30 nM) with the potential to be used for treatment of fragile X syndrome.
MAX-10181 HCl V41315 MAX-10181 HCl MAX-10181 is a novel, potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor, currently under phase 1 clinical trial.
MB 05032 V25082 MB 05032 261365-11-1 MB 05032 is a novel and potent FBPase inhibitor
MB-07133 V11469 MB-07133 685111-92-6 MB-07133 is a novel and potent cytarabine (araC) prodrug
MB-07729 V28949 MB-07729 882755-95-5 MB-07729 is a novel and potent fructose 1,6-bisphosphatase (FBPase) inhibitor
MB-07803 V25086 MB-07803 882757-24-6 MB-07803 is a novel and potent FBPase inhibitor
MB-11362 V25087 MB-11362 1159183-97-7 MB-11362 is a novel and potent HCV nonstructural protein 5B (NS5B) inhibitor
MB-28767 V25088 MB-28767 80558-61-8 MB-28767 is a novel and potent prostaglandin E2 (PGE2) receptor agonist
MB21 V21018 MB21 1870007-38-7 MB21 is a novel and potent inhibitor of dengue type 2 protease
MB710 V25089 MB710 2230044-57-0 MB710 is an aminobenzothiazole analogue and a stabilizer of the oncogenic p53 mutant Y220C.
MB725 V25090 MB725 2230058-99-6 MB725 is a novel and potent inducer of viability reduction
MBA V25091 MBA 116234-45-8 MBA is a novel and potent bioactive molecule
MBC-11 V25092 MBC-11 332863-86-2 MBC-11 is a first-of-its-kind, bone-targeting conjugate of ethyl bisphosphonate covalently bound to the antimetabolite cytarabine (araC).
Contact Us